Eyepoint Pharmaceuticals (EYPT) Short Interest Ratio & Short Volume $0.40 -0.02 (-5.51%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$0.41 +0.00 (+1.11%) As of 10/23/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Eyepoint Pharmaceuticals Short Interest OverviewAs of September 30, 2026, Eyepoint Pharmaceuticals (EYPT) had a short interest of 20.79 million shares sold short, representing 25.42% of the public float. This marks a 4.94% increase in short interest since the prior report. The short interest ratio (days to cover) is 5.4, meaning it would take 5.4 days of the average trading volume of 16.16 million shares to cover all short positions.Current Short Interest20,788,240 sharesPrevious Short Interest19,809,561 sharesChange Vs. Previous Month4.94%Dollar Volume Sold Short$67.98 millionShort Interest Ratio5.4 Days to CoverLast Record DateSeptember 30, 2026Outstanding Shares86,210,000 sharesShort Percent of Float25.42%Today's Trading Volume13,303,908 sharesAverage Trading Volume16,160,523 sharesToday's Volume Vs. Average82% Short Selling Eyepoint Pharmaceuticals? Sign up to receive the latest short interest report for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEYPT Short Interest Over TimeEYPT Days to Cover Over TimeEYPT Percentage of Float Shorted Over Time Eyepoint Pharmaceuticals Tesla Short Interest History & Recent Changes ExportReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/30/202620,788,240 shares $67.98 million +4.9%25.4%5.38 $3.27 9/15/202619,809,561 shares $72.50 million +9.4%24.2%6.43 $3.66 8/31/202618,110,761 shares $81.50 million -1.7%22.1%1.72 $4.50 8/14/202618,426,891 shares $271.80 million +2.3%22.5%9.1 $14.75 7/31/202618,015,023 shares $220.68 million +9.7%22.0%12.35 $12.25 7/15/202616,425,378 shares $227.49 million +8.7%20.7%10.33 $13.85 6/30/202615,114,767 shares $215.76 million +0.3%19.0%9.61 $14.28 6/15/202615,077,303 shares $182.13 million -0.1%19.0%13.84 $12.08 5/29/202615,097,978 shares $205.03 million +6.7%19.0%15.09 $13.58 5/15/202614,152,914 shares $174.79 million -0.2%17.7%16.88 $12.35 Get the Latest News and Ratings for EYPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 4/30/202614,186,473 shares $187.26 million +3.9%17.7%16.59 $13.20 4/15/202613,659,042 shares $199.83 million +2.0%17.2%15.93 $14.63 3/31/202613,385,952 shares $172.54 million +7.3%16.8%14.06 $12.89 3/13/202612,478,689 shares $164.72 million +14.8%15.7%7.52 $13.20 2/27/202610,868,767 shares $190.86 million +14.1%13.6%4.51 $17.56 2/13/20269,529,005 shares $123.31 million +10.3%12.0%7.86 $12.94 1/30/20268,638,845 shares $116.80 million +4.4%10.9%9.51 $13.52 1/15/20268,272,026 shares $131.03 million -4.2%10.5%8.54 $15.84 12/31/20258,632,273 shares $157.71 million +18.1%10.9%6.61 $18.27 12/15/20257,308,090 shares $119.85 million -7.3%9.2%6.63 $16.40 11/28/20257,881,028 shares $116.88 million -8.7%10.0%7.08 $14.83 11/14/20258,632,226 shares $99.96 million +14.2%13.1%5.88 $11.58 10/31/20257,558,136 shares $98.94 million -7.0%11.5%5.85 $13.09 10/15/20258,130,000 shares $95.36 million +1.6%12.3%8.1 $11.73 9/30/20258,000,000 shares $113.92 million -10.0%N/A9.6 $14.24 9/15/20258,890,000 shares $119.21 million +5.2%N/A11.2 $13.41 8/31/20258,450,000 shares $97.77 million +9.9%12.8%11.5 $11.57 8/15/20257,690,000 shares $85.28 million +11.3%N/A9.8 $11.09 7/31/20256,910,000 shares $67.86 million +2.8%10.5%8.9 $9.82 7/15/20256,720,000 shares $66.12 million -3.0%N/A8.4 $9.84 6/30/20256,930,000 shares $65.21 million +2.8%10.5%8.3 $9.41 6/15/20256,740,000 shares $60.86 million -6.0%10.3%8.1 $9.03 5/31/20257,170,000 shares $51.70 million -0.6%11.0%8.6 $7.21 5/15/20257,210,000 shares $41.24 million -28.4%11.1%9.2 $5.72 4/30/202510,070,000 shares $68.68 million -14.8%N/A12.4 $6.82 4/15/202511,820,000 shares $67.02 million +8.1%18.2%14 $5.67 3/31/202510,930,000 shares $59.24 million +0.9%16.8%12.8 $5.42 3/15/202510,830,000 shares $70.61 million +0.9%16.7%12.6 $6.52 2/28/202510,730,000 shares $67.28 million -3.3%16.5%12.4 $6.27 2/15/202511,090,000 shares $72.09 million +3.5%17.1%12.3 $6.50Financial legend: “This is bad, really bad...” (Ad)Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.See Dr. Weiss's full warning before the next crisis hits. 1/31/202510,720,000 shares $82.01 million +1.3%N/A11.9 $7.65 1/15/202510,580,000 shares $81.36 million +2.3%N/A11 $7.69 12/31/202410,340,000 shares $77.03 million +9.9%N/A10.8 $7.45 12/15/20249,410,000 shares $70.20 million +1.7%N/A10.3 $7.46 11/30/20249,250,000 shares $81.86 million -6.4%N/A10.8 $8.85 11/15/20249,880,000 shares $90.60 million +2.1%N/A12.2 $9.17 10/31/20249,680,000 shares $113.84 million +5.6%N/A13.1 $11.76 10/15/20249,170,000 shares $90.60 million +2.7%N/A15.9 $9.88 9/30/20248,930,000 shares $71.35 million -1.9%N/A13.8 $7.99 9/15/20249,100,000 shares $82.81 million -0.1%N/A12.8 $9.10 8/31/20249,110,000 shares $81.53 million -3.9%N/A12.6 $8.95 8/15/20249,480,000 shares $77.74 million -0.7%N/A11.6 $8.20 7/31/20249,550,000 shares $94.35 million -5.3%N/A10.7 $9.88 7/15/202410,080,000 shares $106.24 million +4.7%N/A8.8 $10.54 6/30/20249,630,000 shares $83.78 million +7.2%N/A8.5 $8.70 6/15/20248,980,000 shares $84.23 million +16.0%N/A8.2 $9.38 5/31/20247,740,000 shares $82.90 million -4.8%N/A6.7 $10.71 5/15/20248,130,000 shares $105.20 million +23.2%N/A7 $12.94 4/30/20246,600,000 shares $116.16 million +0.9%N/A5.6 $17.60 4/15/20246,540,000 shares $139.17 million -4.5%N/A6.7 $21.28 3/31/20246,850,000 shares $141.59 million +4.1%N/A7.1 $20.67 3/15/20246,580,000 shares $141.34 million +15.0%N/A6.4 $21.48 2/29/20245,720,000 shares $155.64 million +20.4%N/A4.5 $27.21 2/15/20244,750,000 shares $138.13 million -7.6%N/A2.9 $29.08 1/31/20245,140,000 shares $138.42 million -1.2%N/A3.3 $26.93 1/15/20245,200,000 shares $118.35 million -2.4%N/A3.5 $22.76 12/31/20235,330,000 shares $123.18 million +12.2%N/A3.9 $23.11 12/15/20234,750,000 shares $92.86 million -32.2%N/A3.6 $19.55 11/30/20237,010,000 shares $43.81 million +28.9%25.0%5.9 $6.25 11/15/20235,440,000 shares $36.39 million +1.7%19.4%10.3 $6.69 10/31/20235,350,000 shares $32.21 million +9.0%19.2%10.3 $6.02 10/15/20234,910,000 shares $39.77 million -29.3%17.6%9.3 $8.10 9/30/20236,940,000 shares $55.45 million +12.3%25.1%11.6 $7.99 9/15/20236,180,000 shares $64.77 million +9.2%22.3%10.2 $10.48 8/31/20235,660,000 shares $56.09 million +12.1%20.6%9.5 $9.91 8/15/20235,050,000 shares $71.66 million +3.7%18.8%8.9 $14.19 7/31/20234,870,000 shares $60.88 million +1.9%N/A9.3 $12.50 7/15/20234,780,000 shares $52.44 million -7.7%N/A4.9 $10.97 6/30/20235,180,000 shares $45.07 million +7.5%N/A5.6 $8.70 6/15/20234,820,000 shares $32.73 million +13.2%18.4%5.3 $6.79 5/31/20234,260,000 shares $25.77 million +5.2%16.2%4.8 $6.05 5/15/20234,050,000 shares $24.30 million +11.3%15.4%4.7 $6.00 4/30/20233,640,000 shares $22.86 million -0.3%14.1%4.4 $6.28 4/15/20233,650,000 shares $15.80 million +9.3%14.2%5.3 $4.33 3/31/20233,340,000 shares $9.82 million +19.7%13.0%11 $2.94 3/15/20232,790,000 shares $6.67 million +34.8%10.9%10 $2.39 2/28/20232,070,000 shares $6.91 million No Change8.1%8.1 $3.34 2/15/20232,070,000 shares $7.66 million -4.2%8.1%8.5 $3.70 1/31/20232,160,000 shares $10.07 million +6.9%8.6%9.3 $4.66 1/15/20232,020,000 shares $10.18 million +13.5%8.0%9.4 $5.04Don't lose access to this (Ad)Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.Download your free copy before access ends for good 12/30/20221,780,000 shares $6.23 million +6.0%7.1%12.3 $3.50 12/15/20221,680,000 shares $4.50 million -2.9%6.7%11.6 $2.68 11/30/20221,730,000 shares $5.54 million -3.4%6.9%13.6 $3.20 11/15/20221,790,000 shares $7.91 million -9.1%7.1%14.1 $4.42 10/31/20221,970,000 shares $10.64 million -1.5%N/A16.1 $5.40 10/15/20222,000,000 shares $11.20 million -1.5%7.7%14.3 $5.60 9/30/20222,030,000 shares $16.06 million -0.5%7.8%12.5 $7.91 9/15/20222,040,000 shares $16.30 million +0.5%7.9%12.7 $7.99 8/31/20222,030,000 shares $20.30 million +1.5%7.8%12.7 $10.00 8/15/20222,000,000 shares $22.24 million -8.3%7.7%12.8 $11.12 7/31/20222,180,000 shares $19.90 million +7.4%8.3%13.8 $9.13 7/15/20222,030,000 shares $20.12 million +1.0%7.8%14.4 $9.91 6/30/20222,010,000 shares $15.82 million +2.0%7.7%16.8 $7.87 6/15/20221,970,000 shares $15.62 million -5.3%7.5%16.7 $7.93 5/31/20222,080,000 shares $20.07 million -3.3%8.0%16 $9.65 5/15/20222,150,000 shares $21.26 million -1.4%8.2%14.1 $9.89 4/30/20222,180,000 shares $24.63 million +0.5%8.3%13.4 $11.30 4/15/20222,170,000 shares $27.54 million +0.5%8.3%11.9 $12.69 3/31/20222,160,000 shares $26.24 million +4.9%8.3%9.6 $12.15 3/15/20222,060,000 shares $24.82 million +3.0%7.9%7.9 $12.05 2/28/20222,000,000 shares $19.90 million +3.6%7.7%7.2 $9.95 2/15/20221,930,000 shares $19.59 million -2.5%7.4%6.6 $10.15 1/31/20221,980,000 shares $18.55 million -8.3%7.6%2.4 $9.37 1/15/20222,160,000 shares $21.45 million +11.3%N/A2.7 $9.93 12/31/20211,940,000 shares $23.75 million +0.5%7.4%2.5 $12.24 12/15/20211,930,000 shares $28.27 million -3.5%7.4%2.6 $14.65 11/30/20212,000,000 shares $31.60 million +98.0%8.1%2.9 $15.80 11/15/20211,010,000 shares $14.44 million -34.0%4.2%1.5 $14.30 10/29/20211,530,000 shares $17.55 million +10.9%7.3%11 $11.47 EYPT Short Interest - Frequently Asked Questions What is Eyepoint Pharmaceuticals' current short interest? Short interest is the volume of Eyepoint Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of September 30th, traders have sold 20,788,240 shares of EYPT short. 25.42% of Eyepoint Pharmaceuticals' shares are currently sold short. Learn More on Eyepoint Pharmaceuticals' current short interest. What is a good short interest ratio for Eyepoint Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EYPT shares currently have a short interest ratio of 5.4. Learn More on Eyepoint Pharmaceuticals's short interest ratio. What is a good short interest percentage for Eyepoint Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 25.42% of Eyepoint Pharmaceuticals' floating shares are currently sold short. Is Eyepoint Pharmaceuticals' short interest increasing or decreasing? Eyepoint Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 20,788,240 shares, an increase of 4.9% from the previous total of 19,809,561 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Eyepoint Pharmaceuticals' short interest compare to its competitors? 25.42% of Eyepoint Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceuticals" compare to Eyepoint Pharmaceuticals: Harrow, Inc. (23.75%), Avalyn Pharma Inc. (5.68%), Alto Neuroscience, Inc. (13.38%), Theravance Biopharma, Inc. (3.52%), Seaport Therapeutics, Inc. (6.82%), Cybin Inc. (5.12%), Spyglass Pharma, Inc. (3.75%), Ardelyx, Inc. (11.73%), Gyre Therapeutics, Inc. (1.90%), Achieve Life Sciences, Inc. (17.29%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($75.10 billion), Invesco QQQ ($52.12 billion), iShares Russell 2000 ETF ($25.28 billion), SPDR S&P Biotech ETF ($11.70 billion), Nebius Group N.V. ($10.54 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($9.69 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($9.22 billion), iShares 20+ Year Treasury Bond ETF ($8.80 billion), Financial Select Sector SPDR Fund ($7.65 billion), and Lumentum Holdings Inc. ($7.23 billion). View all of the most shorted stocks. What does it mean to sell short Eyepoint Pharmaceuticals stock? Short selling EYPT is an investing strategy that aims to generate trading profit from Eyepoint Pharmaceuticals as its price is falling. EYPT shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Eyepoint Pharmaceuticals? A short squeeze for Eyepoint Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EYPT, which in turn drives the price of the stock up even further. How often is Eyepoint Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EYPT, twice per month. The most recent reporting period available is September, 30 2026. What do EYPT's short interest metrics mean? Understanding short interest metrics can help you assess how traders are positioning around a stock like EYPT:Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity. More Short Interest Resources from MarketBeat Related Companies Harrow Short Interest Avalyn Pharma Short Interest Alto Neuroscience Short Interest Theravance Biopharma Short Interest Seaport Therapeutics Short Interest Cybin Short Interest Spyglass Pharma Short Interest Ardelyx Short Interest Gyre Therapeutics Short Interest Achieve Life Sciences Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates Short interest data for NASDAQ:EYPT is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 10/9/2026. FINRA publishes updated short interest twice a month. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
